HRP20201815T1 - Nukleinske kiseline za liječenje alergija - Google Patents

Nukleinske kiseline za liječenje alergija Download PDF

Info

Publication number
HRP20201815T1
HRP20201815T1 HRP20201815TT HRP20201815T HRP20201815T1 HR P20201815 T1 HRP20201815 T1 HR P20201815T1 HR P20201815T T HRP20201815T T HR P20201815TT HR P20201815 T HRP20201815 T HR P20201815T HR P20201815 T1 HRP20201815 T1 HR P20201815T1
Authority
HR
Croatia
Prior art keywords
nucleic acid
seq
acid molecule
treatment
pharmaceutical composition
Prior art date
Application number
HRP20201815TT
Other languages
English (en)
Croatian (hr)
Inventor
William Hearl
Teri Heiland
Original Assignee
Immunomic Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics, Inc. filed Critical Immunomic Therapeutics, Inc.
Publication of HRP20201815T1 publication Critical patent/HRP20201815T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HRP20201815TT 2012-06-15 2012-06-15 Nukleinske kiseline za liječenje alergija HRP20201815T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2012/042552 WO2013187906A1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies
EP12878776.9A EP2861240B1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Publications (1)

Publication Number Publication Date
HRP20201815T1 true HRP20201815T1 (hr) 2021-02-19

Family

ID=49758576

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201815TT HRP20201815T1 (hr) 2012-06-15 2012-06-15 Nukleinske kiseline za liječenje alergija

Country Status (20)

Country Link
US (3) US9744230B2 (enExample)
EP (2) EP3808361A1 (enExample)
JP (1) JP5807994B2 (enExample)
KR (2) KR102107646B1 (enExample)
CN (2) CN107937423A (enExample)
AU (3) AU2012382406B2 (enExample)
BR (1) BR112014031327B1 (enExample)
CA (1) CA2876824C (enExample)
CY (1) CY1123769T1 (enExample)
DK (1) DK2861240T3 (enExample)
ES (1) ES2831723T3 (enExample)
HR (1) HRP20201815T1 (enExample)
HU (1) HUE052481T2 (enExample)
IL (4) IL236174B (enExample)
LT (1) LT2861240T (enExample)
PL (1) PL2861240T3 (enExample)
PT (1) PT2861240T (enExample)
RS (1) RS61098B1 (enExample)
SI (1) SI2861240T1 (enExample)
WO (1) WO2013187906A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
PL2861240T3 (pl) * 2012-06-15 2021-07-05 Immunomic Therapeutics, Inc. Kwasy nukleinowe do leczenia alergii
NZ707615A (en) 2012-10-30 2019-01-25 Aravax Pty Ltd Novel immunotherapeutic molecules and uses thereof
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
EP3157558A2 (en) * 2014-06-23 2017-04-26 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
TWI752930B (zh) 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 抗原特異性tcr的新生成
CN110418650A (zh) * 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
EP3612556B8 (en) * 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018204534A1 (en) * 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
CN111465328A (zh) 2017-07-18 2020-07-28 前品牌股份有限公司 制备混合型变应原组合物的方法
EP3779443A4 (en) * 2018-04-06 2022-05-04 Slsbio Co., Ltd. NEW IMMUNOGLOBULIN E EPITOPE, BINDING ANTIBODY AND KIT FOR THE ANALYSIS OF IMMUNOGLOBULIN E IN A SAMPLE CONTAINING IT
WO2019216394A1 (ja) * 2018-05-11 2019-11-14 アステラス製薬株式会社 ダニアレルギー治療のための核酸
CA3099505A1 (en) * 2018-05-11 2019-11-14 Astellas Pharma Inc. Nucleic acid for treating crustacean allergy
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. アレルゲンを含む改善されたlamp構築物
US11766477B2 (en) 2019-01-23 2023-09-26 Societe Des Produits Nestle S.A. Methods for making mixed allergen compositions
CN113631231A (zh) * 2019-03-13 2021-11-09 普梭梅根公司 用于过敏治疗的基于表位的方法和克罗恩病的抑制剂
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
JP2024517463A (ja) * 2021-05-04 2024-04-22 ソヴィダ ソリューションズ リミテッド ニコチンアミドアデニンジヌクレオチド(nad)組成物、それらの製造方法、及びそれらの使用方法
CN117795081A (zh) * 2021-08-06 2024-03-29 花王株式会社 利用snare的核酸构建体
FI131854B1 (en) 2023-05-29 2026-01-12 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic activity and greater survival

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD335810S (en) 1990-07-02 1993-05-25 Dick-Ming Asien Handle for luggage or similar article
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6090386A (en) 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
AU5668194A (en) * 1992-11-12 1994-06-08 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP3649460B2 (ja) 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンCry j IIエピトープ
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
CA2241918C (en) 1995-12-29 2008-12-02 University Of Arkansas Peanut allergens and methods
CA2258125C (en) 1996-06-14 2010-11-23 Meiji Milk Products Co., Ltd. T-cell epitope peptides
US20020142978A1 (en) * 2000-04-07 2002-10-03 Eyal Raz Synergistic improvements to polynucleotide vaccines
WO2002074250A2 (en) 2001-03-16 2002-09-26 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
ES2404689T3 (es) * 2001-04-05 2013-05-28 The Johns Hopkins University Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2
US20060003148A1 (en) 2004-06-30 2006-01-05 Zwynenburg James L Interlocking polymeric foam floor underlayment and process for making
US20060216315A1 (en) * 2005-03-16 2006-09-28 Yoo Tai J Cockroach allergen gene expression and delivery systems and uses
US20090304738A1 (en) 2005-06-16 2009-12-10 Moran Thomas M Methods for Enhancing Immune Responses
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
WO2007024026A1 (ja) * 2005-08-25 2007-03-01 Taiho Pharmaceutical Co., Ltd. T細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
US20080006554A1 (en) 2006-07-07 2008-01-10 Medtronic Vascular, Inc. Packaging assembly for a catheter
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
EP2331568B1 (en) * 2008-09-10 2014-09-03 ITH Immune Therapy Holdings AB Treating inflammatory conditions
PL2861240T3 (pl) * 2012-06-15 2021-07-05 Immunomic Therapeutics, Inc. Kwasy nukleinowe do leczenia alergii
CN110418650A (zh) * 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
EP3612556B8 (en) * 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Improved lamp constructs

Also Published As

Publication number Publication date
US20160271245A1 (en) 2016-09-22
RS61098B1 (sr) 2020-12-31
AU2019250227A1 (en) 2019-11-07
JP2015521467A (ja) 2015-07-30
US20220081474A1 (en) 2022-03-17
CN104519896A (zh) 2015-04-15
EP2861240B1 (en) 2020-09-09
IL236174B (en) 2019-11-28
ES2831723T3 (es) 2021-06-09
AU2012382406A2 (en) 2015-04-16
CN104519896B (zh) 2017-11-10
US20180009857A1 (en) 2018-01-11
IL236174A0 (en) 2015-01-29
IL270260B (en) 2020-08-31
PL2861240T3 (pl) 2021-07-05
DK2861240T3 (da) 2020-09-28
WO2013187906A1 (en) 2013-12-19
PT2861240T (pt) 2020-11-09
CY1123769T1 (el) 2022-05-27
EP2861240A4 (en) 2016-03-16
AU2018200625B2 (en) 2019-09-19
KR102107646B1 (ko) 2020-05-08
AU2018200625A1 (en) 2018-02-15
US10072053B2 (en) 2018-09-11
SI2861240T1 (sl) 2021-04-30
LT2861240T (lt) 2021-01-25
CA2876824A1 (en) 2013-12-19
KR102386481B1 (ko) 2022-04-14
KR20150032286A (ko) 2015-03-25
AU2012382406A1 (en) 2014-12-18
CA2876824C (en) 2020-07-21
BR112014031327A2 (pt) 2017-06-27
JP5807994B2 (ja) 2015-11-10
IL270262A (en) 2019-12-31
CN107937423A (zh) 2018-04-20
AU2019250227B2 (en) 2021-10-21
IL270261B (en) 2021-03-25
BR112014031327B1 (pt) 2022-02-01
KR20200047792A (ko) 2020-05-07
EP2861240A1 (en) 2015-04-22
EP3808361A1 (en) 2021-04-21
US9744230B2 (en) 2017-08-29
AU2012382406B2 (en) 2017-12-07
HUE052481T2 (hu) 2021-04-28

Similar Documents

Publication Publication Date Title
BR112013019975A2 (pt) proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
CY1122195T1 (el) Πολυπεπτιδια συντηξης σερπινης και μεθοδοι χρησης αυτων
US20240150409A1 (en) Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
BR112013032723A2 (pt) antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
EA201200515A1 (ru) Полипептиды и их применение
WO2010150233A3 (en) Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
BR112013029409A8 (pt) produtos farmacêuticos de peptídeo melhorados para resistência à insulina
EA201170635A1 (ru) Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii
BR112014019901A8 (pt) Proteínas de fator viii recombinante
BR112015003947A8 (pt) Proteínas de fusão e métodos para tratar, prevenir ou melhorar dor
CO6690759A2 (es) Anticuerpos, fragmentos de unión o derivados de los mismos que se unen específicamente a la proteína 4-1 bb
HRP20192314T1 (hr) Pripravci faktora viii i postupci pripreme i njihove uporabe
GT200500254A (es) Proceso para la concentracion de anticuerpos y productos terapeùticos relacionados.
DK2027152T3 (da) Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
MX2014007516A (es) Procesos que utilizan vlps con capsides resistentes a hidrolasas.
CO6210831A2 (es) Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
RU2015126105A (ru) Модифицированные суперспиральные белки с улучшенными свойствами
AR069584A1 (es) Proteinas de elastasa recombinantes y sus metodos de preparacion y su uso